Over 30 Years:

The Mectizan®

Donation Program

Our Commitment:

“as much as needed, for as long as needed..."

For centuries, river blindness (onchocerciasis) plagued remote communities in Africa, Latin America and Yemen, and there was no answer to this affliction.

This all began to change in the mid-to-late 1970s, when Dr. William Campbell of MSD Research Laboratories suggested the use of ivermectin (later named Mectizan) for river blindness in humans. Following the breakthrough lab work by Dr. Campbell, another MSD researcher, Dr. Mohammed Aziz, championed the clinical development of Mectizan. Dr. Aziz led the collaboration with the World Health Organization (WHO) in the early 1980s to design and implement field studies in West Africa that, ultimately, proved the effectiveness of the drug against river blindness.

In 1987, MSD committed to donate Mectizan - as much as needed, for as long as needed - with the goal to help eliminate river blindness.

In order to reach this goal, MSD leaders recognized that many organizations with unique skills would need to work together as a team. To enable this collaboration, MSD established the Mectizan Donation Program (MDP), a ground-breaking public-private partnership. Operating from the Atlanta-based Task Force for Global Health, the MDP coordinates technical and operational activities between MSD, WHO, the World Bank, and a range of public and private stakeholders.

Building on the successful implementation of the river blindness program, in 1998 MSD expanded its commitment to include donating Mectizan for another disease, lymphatic filariasis (LF), also known as elephantiasis, in African countries and Yemen where it co-exists with river blindness. For LF, Mectizan is administered with albendazole, a drug donated by GSK.

In November 2017, in support of new WHO guidelines, MSD announced an expansion of the MDP to reach up to an additional 100 million people per year through 2025 as part of the global effort to eliminate LF.

More than thirty years later, the results of the MDP speak for themselves. Several countries in Africa are making significant progress towards eliminating both diseases. In Latin America, four countries – Colombia, Ecuador, Mexico and Guatemala – have received WHO verification of river blindness elimination. LF has now been eliminated in Togo and Yemen. Both river blindness and LF are on WHO’s list of neglected tropical diseases targeted for elimination globally.

Today, the MDP is the longest-running, disease-specific drug donation program of its kind and has been influential in the development of a number of other drug donation programs. And, the MDP's community-directed strategy used to distribute Mectizan has enabled add-on health services to be introduced in remote communities where health services are limited. The program reaches more than 300 million people in the affected areas annually, with more than 3.4 billion treatments donated since 1987.

“This pioneering program has changed the face of global health over the past three decades,” said Yao Sodahlon, head of the MDP. “When I visit communities where Mectizan is donated, I can see how the program has helped alleviate suffering and allowed people to live better and healthier lives.”

According to Uche Amazigo, former director of the African Programme for Onchocerciasis Control,

"by engaging the people, the treatment coverage increased significantly."

People in the communities are an integral part of the distribution process in the more than 146,000 communities where Mectizan has been distributed.

Over 30 years later, the results of this program speak for themselves.

MORE THAN
BILLION CUMULATIVE TREATMENTS
MORE THAN

COMMUNITIES

Through the efforts of a variety of partners, more than 3.4 billion treatments have been donated to more than 146,000 communities in 29 countries in Africa, six countries in Latin America, and in Yemen. River blindness transmission has been interrupted - meaning no new cases have been identified - in four of the six affected countries in Latin America and regions in five African countries. The program reaches more than 300 million people annually.

Today, the MDP is the longest-running, disease-specific drug donation program of its kind.

We are humbled by the great work of the alliance of partners to protect future generations from a disease that carries devastating implications for people, families, health care systems and local economies.
- Ken Frazier
Chairman and CEO, MSD